ĐÁNH GIÁ HIỆU QUẢ HÓA XẠ TRỊ ĐỒNG THỜI TRƯỚC PHẪU THUẬT ĐIỀU TRỊ UNG THƯ TRỰC TRÀNG GIAI ĐOẠN II, III

Abstract

Objective: Evaluation of treatment outcomes of neoadjuvant concurrent chemoradiation therapy for patients with stage II and III rectal cancer and commented on some of the side effects and toxicity of this treatment. Subjects and methods: A descriptive retrospective combines prospective study in 48 patients with stage II and III rectal cancer who receive radiation therapy dose of 50.4 Gy in combination with Capecitabine at the dose of 825mg/m2 x 2times/day on the days of radiation therapy, surgery is performed 4-6 weeks after the end of concurrent chemoradiation therapy. Results: The overall response rate after treatment reached 83.4%. All patient underwent definitive surgery, of which 87.5% have surgery to preserve the anal sphincter. Evaluation of histopathology of the patient after surgery: 25% with a complete response; 85.4% downstage primary tumours and 91.7% downstage nodal. Toxicity is mainly encountered at level 1,2: grade 1 anaemia is 39.6%, grade 1 leukopenia is 6,3%. Other common side effects are grade 1 cystitis (20.8%) and grade 1 radiation dermatitis (37.5%). No toxicity degree 3,4. Conclusion: Concurrent chemoradiation therapy preoperative with Capecitabine is the effective, safe and less toxicity treatment for patients with stage II and III rectal cancer.